A decision is expected in the fourth quarter of 2025.

Does the dose of Rybelsus I take, 3 milligrams (mg), 7 mg, or 14 mg, affect my risk of side effects? It’s possible. In studies, some people chose to stop taking Rybelsus because of digestion ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Eli Lilly stated that participants taking a 36 mg dose of the oral diabetes and obesity treatment 'orforglipron' in Phase 3 clinical trials lost an average of 7.3 kg over 9 months. This Phase 3 ...

At 40 weeks, the 3 mg orforglipron group lost 4.7% of their body weight from baseline ... Pratley “[Orforglipron] seems superior to oral semaglutide (Rybelsus, Novo Nordisk) in terms of efficacy ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

Additionally, patients taking the highest 36 mg dose lost an average of 16 pounds, which translates to 7.9% of their total ... NVO also markets Rybelsus as an oral medication for adults with ...

On average, patients who took 12 mg doses lost 11.5 lbs, or 5.8% of their body weight, while patients who were administered 36 mg doses lost 15.8 lbs, or 7.6% of their body weight ... an FDA-approved ...